NASDAQ:XLO
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc.'s revenue grew 589.9% in fiscal 2025 to $43.8M while operating margin rose to −95.9%. Free cash flow was −$5.5M, −12.6% of revenue.Summary generated from Xilio Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$43.8M
Revenue growth+589.9%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−95.9%
Net margin−80.1%
ROICn/a
Return on equity−132.5%
Debt / equityn/a
Free cash flow−$5.5M
FCF margin−12.6%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | 6 | 44 |
| Operating income | −75 | −89 | −79 | −61 | −42 |
| Net income | −76 | −88 | −76 | −58 | −35 |
| Free cash flow | −82 | −78 | −69 | −18 | −6 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 4Insider transaction report
Jun 12, 2026 - 8-KDirector or officer change
Jun 12, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 8-KResults of operations and financial condition
May 12, 2026 - DEF 14AProxy statement
Apr 28, 2026